BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter. 2008;13:532-541. [PMID: 19166419 DOI: 10.1111/j.1523-5378.2008.00643.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 61] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 2010;28:1001-13. [PMID: 20936884 DOI: 10.2165/11537410-000000000-00000] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
2 Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics 2012;22:159-65. [PMID: 22027650 DOI: 10.1097/FPC.0b013e32834d4962] [Cited by in Crossref: 100] [Cited by in F6Publishing: 42] [Article Influence: 11.1] [Reference Citation Analysis]
3 Rakesh TP. Proton pump inhibitors: use, misuse and concerns about long-term therapy. Clin J Gastroenterol 2011;4:53-9. [DOI: 10.1007/s12328-011-0208-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
4 Hong J, Shu X, Liu D, Zhu Y, Xie C, Xie Y, Zhang K, Wang A, Xiong H, Zeng H. Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial. J Antimicrob Chemother. 2016;71:2280-2285. [PMID: 27107097 DOI: 10.1093/jac/dkw118] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
5 Liang J, Li J, Han Y, Xia J, Yang Y, Li W, Zhang S, Wu Y, Yuan Y, Li Z, Du Y, Chen M, Chen B, Jiang B, Bai Y, Wen Q, Wu K, Fan D. Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open-Label, Phase IV Trial. Helicobacter 2012;17:458-65. [DOI: 10.1111/j.1523-5378.2012.00971.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
6 Toda R, Shiramoto M, Komai E, Yoshii K, Hirayama M, Kawabata Y. Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers. The Journal of Clinical Pharmacology 2018;58:425-33. [DOI: 10.1002/jcph.1038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Pan X, Li Y, Qiu Y, Tang Q, Qian B, Yao L, Shi R, Zhang G. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: A 1-week, randomized, open-label study in chinese adults. Clinical Therapeutics 2010;32:2003-11. [DOI: 10.1016/j.clinthera.2010.11.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
8 Miftahussurur M, Doohan D, Syam AF, Nusi IA, Subsomwong P, Waskito LA, Maulahela H, Akil F, Uwan WB, Siregar G, Fauzia KA, Rezkitha YAA, Rahman A, Wibawa IDN, Saudale AMJ, Richardo M, Sugihartono T, Chomariyati A, Bramantoro T, Uchida T, Yamaoka Y. CYP2C19 Polymorphisms in Indonesia: Comparison among Ethnicities and the Association with Clinical Outcomes. Biology (Basel) 2021;10:300. [PMID: 33917299 DOI: 10.3390/biology10040300] [Reference Citation Analysis]
9 Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am. 2010;39:465-480. [PMID: 20951912 DOI: 10.1016/j.gtc.2010.08.007] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
10 Li Y, Xu J, Xu C, Qin Z, Li S, Hu L, Yao Z, Gonzalez FJ, Yao X. Metabolism and disposition of corylifol A from Psoralea corylifolia: metabolite mapping, isozyme contribution, species differences and identification of efflux transporters for corylifol A-O-glucuronide in HeLa1A1 cells. Xenobiotica 2020;50:997-1008. [PMID: 32116078 DOI: 10.1080/00498254.2020.1732496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Chen H, Dang Y, Zhou X, Liu B, Liu S, Zhang G. Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication: A Meta-Analysis. Medicine (Baltimore). 2016;95:e2750. [PMID: 26886617 DOI: 10.1097/md.0000000000002750] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 5.2] [Reference Citation Analysis]
12 Molina-Infante J, Shiotani A. Practical Aspects in Choosing a Helicobacter pylori Therapy. Gastroenterol Clin North Am 2015;44:519-35. [PMID: 26314666 DOI: 10.1016/j.gtc.2015.05.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
13 Jenkins H, Jenkins R, Patat A. Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. Clin Drug Investig 2017;37:311-6. [PMID: 27928738 DOI: 10.1007/s40261-016-0488-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
14 Georgopoulos SD, Papastergiou V, Karatapanis S. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era. Expert Opin Pharmacother. 2015;16:2307-2317. [PMID: 26330278 DOI: 10.1517/14656566.2015.1084503] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
15 Ahn HJ, Kim DP, Chu MS, Yun HJ, Kim SH, Lee SW, Lee DS. Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections. Gastroenterol Res Pract 2017;2017:1654907. [PMID: 28539935 DOI: 10.1155/2017/1654907] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Shah SC, Tepler A, Chung CP, Suarez G, Peek RM Jr, Hung A, Roumie C, Narula N. Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis. Gastroenterology 2021:S0016-5085(21)03338-2. [PMID: 34358488 DOI: 10.1053/j.gastro.2021.07.043] [Reference Citation Analysis]
17 Tantry US, Kereiakes DJ, Gurbel PA. Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv. 2011;4:365-380. [PMID: 21511216 DOI: 10.1016/j.jcin.2010.12.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
18 Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22. [PMID: 28464347 DOI: 10.1111/hel.12392] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
19 Franciosi JP, Mougey EB, Williams A, Gomez Suarez RA, Thomas C, Creech CL, George K, Corao D, Lima JJ. Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment. Eur J Pediatr 2018;177:69-77. [PMID: 29209919 DOI: 10.1007/s00431-017-3051-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
20 Unler GK, Teke Ozgur G, Gokturk HS, Karakoca A, Erinanc OH. A Comparison of Five Different Treatment Regimens as the First-Line Treatment of Helicobacter pylori in Turkey. Helicobacter 2016;21:279-85. [DOI: 10.1111/hel.12285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Sasaki M, Ogasawara N, Utsumi K, Kawamura N, Kamiya T, Kataoka H, Tanida S, Mizoshita T, Kasugai K, Joh T. Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. J Clin Biochem Nutr. 2010;47:53-58. [PMID: 20664731 DOI: 10.3164/jcbn.10-10] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
22 El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14:447-460. [PMID: 29620484 DOI: 10.1080/17425255.2018.1461835] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 16.0] [Reference Citation Analysis]
23 Yang L, Zou A, Wu H, Guo H, Zhang F, Zou B, Wang J. Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pylori. Biomed Res Int 2021;2021:6150628. [PMID: 33937401 DOI: 10.1155/2021/6150628] [Reference Citation Analysis]
24 Zhang L, Mei Q, Li QS, Hu YM, Xu JM. The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people: CYP2C19 and IL-1 genotypes in H. pylori cure rate. Journal of Clinical Pharmacy and Therapeutics 2010;35:713-22. [DOI: 10.1111/j.1365-2710.2009.01140.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
25 Shimoyama T, Chinda D, Sawada Y, Komai K, Chiba H, Saito Y, Sasaki Y, Matsuzaka M, Fukuda S. Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. Intern Med 2017;56:1621-7. [PMID: 28674348 DOI: 10.2169/internalmedicine.56.7823] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
26 Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: A meta-analysis of randomized clinical trials. PLoS One. 2013;8:e62162. [PMID: 23646118 DOI: 10.1371/journal.pone.0062162] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
27 Furuta T, Sugimoto M, Shirai N. Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19. Mol Diagn Ther. 2012;16:223-234. [PMID: 22873740 DOI: 10.2165/11634960-000000000-00000] [Reference Citation Analysis]
28 Kahramanoğlu Aksoy E, Pirinçci Sapmaz F, Göktaş Z, Uzman M, Nazlıgül Y. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen. Med Princ Pract 2017;26:523-9. [PMID: 29131124 DOI: 10.1159/000484930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
29 Yokota H, Sato K, Okuda Y, Kobayashi H, Takeda M, Asano M, Ito H, Miura M. Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer. Clin Lung Cancer 2017;18:e433-9. [PMID: 28579188 DOI: 10.1016/j.cllc.2017.05.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
30 Selgrad M, Kandulski A, Malfertheiner P. Helicobacter pylori: diagnosis and treatment. Curr Opin Gastroenterol. 2009;25:549-556. [PMID: 19696666 DOI: 10.1097/mog.0b013e32833159f2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
31 Buzás GM. First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective. World J Gastroenterol. 2010;16:3865-3870. [PMID: 20712046 DOI: 10.3748/wjg.v16.i31.3865] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
32 Alkim H, Iscan M, Oz F. Effectiveness of ranitidine bismuth citrate and proton pump inhibitor based triple therapies of Helicobacter pylori in Turkey. Libyan J Med. 2011;6. [PMID: 21912572 DOI: 10.3402/ljm.v6i0.8412] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
33 Tornio A, Backman JT. Cytochrome P450 in Pharmacogenetics: An Update. Adv Pharmacol 2018;83:3-32. [PMID: 29801580 DOI: 10.1016/bs.apha.2018.04.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 18.0] [Reference Citation Analysis]
34 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol 2014;20:9898-911. [PMID: 25110420 DOI: 10.3748/wjg.v20.i29.9898] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 46] [Article Influence: 9.2] [Reference Citation Analysis]
35 Gawrońska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M, Drozdzik M. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol 2012;68:1267-74. [PMID: 22418828 DOI: 10.1007/s00228-012-1252-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
36 Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;CD008337. [PMID: 24338763 DOI: 10.1002/14651858.cd008337.pub2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
37 Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther. 2015;6:183-198. [PMID: 26558152 DOI: 10.4292/wjgpt.v6.i4.183] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
38 Tariq H, Patel H, Kamal MU, Abbas N, Ameen M, Azam S, Kumar K, Ravi M, Vootla V, Shaikh D, Amanchi V, Hussain AN, Makker J. Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori. Clin Exp Gastroenterol 2020;13:25-33. [PMID: 32158248 DOI: 10.2147/CEG.S239343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
39 Franciosi JP, Mougey EB, Williams A, Gomez-Suarez RA, Thomas C, Creech CL, George K, Corao D, Lima JJ. Association Between CYP2C19*17 Alleles and pH Probe Testing Outcomes in Children With Symptomatic Gastroesophageal Reflux. J Clin Pharmacol 2018;58:89-96. [PMID: 28884817 DOI: 10.1002/jcph.977] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
40 Ke H, Li J, Lu B, Yang C, Wang J, Wang Z, Liu L, Chen Y. The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy. Helicobacter 2021;26:e12768. [PMID: 33089598 DOI: 10.1111/hel.12768] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Sung J, Kim N, Park YH, Hwang YJ, Kwon S, Na G, Choi JY, Kang JB, Kim HR, Kim J, Lee DH. Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with for Helicobacter pylori Eradication Failure. Korean J Gastroenterol 2017;69:109. [DOI: 10.4166/kjg.2017.69.2.109] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
42 Li Y, Xu C, Xu J, Qin Z, Li S, Hu L, Yao Z, Gonzalez FJ, Yao X. Characterization of metabolic activity, isozyme contribution and species differences of bavachin, and identification of efflux transporters for bavachin- O -glucuronide in HeLa1A1 cells. Journal of Pharmacy and Pharmacology 2020;72:1771-86. [DOI: 10.1111/jphp.13324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
43 Ji CR, Liu J, Li YY, Qiao C, Qu JY, Hu JN, Lin MJ, Ji R, Li LX, Zuo XL, Li YQ. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. J Dig Dis 2020;21:549-57. [PMID: 32833285 DOI: 10.1111/1751-2980.12934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Mori H, Suzuki H. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. J Neurogastroenterol Motil. 2019;25:6-14. [PMID: 30504527 DOI: 10.5056/jnm18139] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
45 Ma JD, Lee KC, Kuo GM. Clinical Application of Pharmacogenomics. Journal of Pharmacy Practice 2012;25:417-27. [DOI: 10.1177/0897190012448309] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
46 Lee SW, Moon SJ, Kim SH, Jung SH, Song KH, Kim SM, Sung JK, Lee DS. The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori. Medicine (Baltimore) 2020;99:e22137. [PMID: 32957336 DOI: 10.1097/MD.0000000000022137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
47 Costa S, Soares JB, Gonçalves R. Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2017;29:1258-63. [PMID: 28877088 DOI: 10.1097/MEG.0000000000000960] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
48 Hagymási K, Müllner K, Herszényi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2011;12:873-888. [PMID: 21692617 DOI: 10.2217/pgs.11.4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
49 Deguchi H, Yamazaki H, Yamamoto Y, Fukuhara S. Association between parental history of Helicobacter pylori treatment failure and treatment failure in the offspring. Journal of Gastroenterology and Hepatology 2019;34:2112-7. [DOI: 10.1111/jgh.14774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
50 Lee JH, Jung HY, Choi KD, Song HJ, Lee GH, Kim JH. The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole. Gut Liver. 2010;4:201-206. [PMID: 20559522 DOI: 10.5009/gnl.2010.4.2.201] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
51 Lee JY, Kim N, Kim MS, Choi YJ, Lee JW, Yoon H, Shin CM, Park YS, Lee DH, Jung HC. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci. 2014;59:1235-1243. [PMID: 24599773 DOI: 10.1007/s10620-014-3093-7] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 9.1] [Reference Citation Analysis]
52 Funck-brentano C, Szymezak J, Steichen O, Ducint D, Molimard M, Remones V, Azizi M, Gaussem P. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Archives of Cardiovascular Diseases 2013;106:661-71. [DOI: 10.1016/j.acvd.2013.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
53 Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1166] [Cited by in F6Publishing: 834] [Article Influence: 233.2] [Reference Citation Analysis]
54 Molina-Infante J, Rodriguez-Sanchez J, Martinek J, van Rhijn BD, Krajciova J, Rivas MD, Barrio J, Moawad FJ, Martinez-Alcalá C, Bredenoord AJ, Zamorano J, Dellon ES. Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis. Am J Gastroenterol 2015;110:1567-75. [PMID: 26416193 DOI: 10.1038/ajg.2015.314] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
55 Furuta T, Sugimoto M, Shirai N. Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19. Mol Diagn Ther 2012;16:223-34. [PMID: 22873740 DOI: 10.1007/BF03262211] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
56 Piatkov I, Jones T, Rochester C. Cytochrome P450 loss-of-function polymorphism genotyping on the Agilent Bioanalyzer and clinical application. Pharmacogenomics 2009;10:1987-94. [PMID: 19958097 DOI: 10.2217/pgs.09.127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
57 Aung AK, Haas DW, Hulgan T, Phillips EJ. Pharmacogenomics of antimicrobial agents. Pharmacogenomics 2014;15:1903-30. [PMID: 25495412 DOI: 10.2217/pgs.14.147] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
58 Nguyen CT, Davis KA, Nisly SA, Li J. Treatment of Helicobacter pylori in Special Patient Populations. Pharmacotherapy 2019;39:1012-22. [DOI: 10.1002/phar.2318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
59 Lee JY, Kim N. [Future trends of Helicobacter pylori eradication therapy in Korea]. Korean J Gastroenterol. 2014;63:158-170. [PMID: 24651589 DOI: 10.4166/kjg.2014.63.3.158] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
60 Zhang M. High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol. 2015;21:13432-13437. [PMID: 26730153 DOI: 10.3748/wjg.v21.i48.13432] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 21] [Article Influence: 6.4] [Reference Citation Analysis]
61 Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol. 2014;20:10338-10347. [PMID: 25132750 DOI: 10.3748/wjg.v20.i30.10338] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]